Over 80% of human diseases have their root cause in genetic mutations. While the gene therapy space has grown exponentially in the past 15 years, 99.5% of gene therapies developed fail clinical trials. Much of this failure is attributable to toxic and ineffective delivery systems.
At Crane Biosciences, we build safe, effective, and targeted delivery systems to enable a new generation of gene therapies.
Deep-tech Engineer with business background, 2x founder, >$1.5Mn raised
PhD in Molecular Biology from the Francis Crick Institute, Marie Curie Fellow
PhD in Chemistry from Vanderbilt University with focus on computational peptide design
